Equities analysts forecast that Haemonetics Co. (NYSE:HAE) will report earnings per share (EPS) of $0.77 for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Haemonetics’ earnings. The lowest EPS estimate is $0.74 and the highest is $0.82. Haemonetics reported earnings per share of $0.63 during the same quarter last year, which would suggest a positive year-over-year growth rate of 22.2%. The company is expected to report its next quarterly earnings report on Tuesday, February 4th.
On average, analysts expect that Haemonetics will report full-year earnings of $3.16 per share for the current year, with EPS estimates ranging from $3.15 to $3.18. For the next year, analysts anticipate that the business will report earnings of $3.81 per share, with EPS estimates ranging from $3.65 to $4.00. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Haemonetics.
Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Friday, November 1st. The medical instruments supplier reported $0.87 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.72 by $0.15. The firm had revenue of $252.57 million during the quarter, compared to analyst estimates of $249.77 million. Haemonetics had a return on equity of 24.59% and a net margin of 6.90%.
Haemonetics stock traded up $1.29 during mid-day trading on Wednesday, hitting $119.52. The company’s stock had a trading volume of 11,824 shares, compared to its average volume of 266,526. The firm has a market capitalization of $6.11 billion, a PE ratio of 49.98, a price-to-earnings-growth ratio of 2.81 and a beta of 0.77. Haemonetics has a 1 year low of $80.24 and a 1 year high of $140.36. The stock’s fifty day moving average is $122.11 and its two-hundred day moving average is $121.16. The company has a current ratio of 2.37, a quick ratio of 1.35 and a debt-to-equity ratio of 0.54.
In other news, SVP Jacqueline Scanlan sold 1,531 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $127.44, for a total value of $195,110.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO William P. Mr. Burke sold 7,164 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $125.80, for a total transaction of $901,231.20. The disclosure for this sale can be found here. Insiders have sold a total of 70,131 shares of company stock worth $8,512,917 in the last quarter. 1.32% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Alpha Windward LLC purchased a new position in Haemonetics in the second quarter valued at about $29,000. Financial Gravity Wealth Inc. purchased a new stake in shares of Haemonetics during the 2nd quarter worth approximately $40,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Haemonetics during the 2nd quarter worth approximately $42,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in shares of Haemonetics in the 3rd quarter worth approximately $58,000. Finally, Smithfield Trust Co. grew its holdings in shares of Haemonetics by 18.8% in the 3rd quarter. Smithfield Trust Co. now owns 570 shares of the medical instruments supplier’s stock worth $72,000 after acquiring an additional 90 shares during the period. Institutional investors own 96.67% of the company’s stock.
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.